7.7.9. summary evidence recommendations metastatic disease. summary evidenceleenfortumab vedotin combination pembrolizumab first-line setting demonstrated significant survival benefit compared chemotherapy.1the combination cisplatin gemcitabine plus nivolumab first-line setting demonstrated significant survival benefit compared chemotherapy alone.1bin first-line setting, ps presence absence visceral metastases independent prognostic factors survival.1bin second-line setting, negative prognostic factors are: liver metastasis, ps ≥ 1 low haemoglobin (< 10 g/dl).1bcisplatin-containing combination chemotherapy achieve median survival 14 months, long-term dfs reported ~15% patients nodal disease good ps.1bsingle-agent chemotherapy provides low response rates usually short duration.2acarboplatin combination chemotherapy less effective cisplatin-based chemotherapy terms complete response survival.2athere defined standard therapy platinum chemotherapy-unfit patients advanced metastatic uc.2bpost-chemotherapy surgery partial complete response may contribute long-term dfs highly selected patients.3zoledronic acid denosumab approved supportive treatment case bone metastases cancer types including uc, reduce delay skeletal related events.1bpd-1 inhibitor pembrolizumab approved patients progressed previous platinum-based chemotherapy based results phase iii trial.1benfortumab vedotin prior platinum chemotherapy checkpoint inhibitor immunotherapy demonstrated significant survival benefit compared chemotherapy.1bpd-1 inhibitor atezolizumab approved patients advanced metastatic uc unfit cisplatin-based chemotherapy case high pd-l1 expression defined tumour-infiltrating immune cells covering ≥ 5% tumour area using sp142 assay.1bpd-1 inhibitor pembrolizumab approved patients advanced metastatic uc unfit platinum-based chemotherapy case high pd-l1 expression defined cps ≥ 10 using dako 22c33 platform (ema; fda approval independent pd-l1 status).1bthe combination chemotherapy plus pembrolizumab atezolizumab combination durvalumab tremelimumab demonstrated os survival benefit compared platinum-based chemotherapy alone.1bswitch maintenance pd-l1 inhibitor avelumab demonstrated significant os benefit patients achieving least stable disease first-line platinum-based chemotherapy.1b recommendationsstrength ratingfirst-line treatment eligible combination therapyuse antibody drug conjugate enfortumab vedotin (ev) combination checkpoint inhibitor (cpi) pembrolizumab.strongif contraindications ev ev available:offer platinum-containing combination chemotherapy (cisplatin carboplatin plus gemcitabine) followed maintenance treatment cpi avelumab patients least stable disease chemotherapy.strongif contraindications ev (or ev available) cisplatin-eligible:consider cisplatin/gemcitabine combination cpi nivolumab.strongif contraindications checkpoint inhibitor therapy:use platinum-containing combination chemotherapy (cisplatin carboplatin plus gemcitabine).strongfirst-line treatment eligible combination therapyconsider single agent cpi pembrolizumab atezolizumab case high pd-1 expression. (for definitions see text).weaksecond-line treatmentafter prior ev + cpioffer platinum-containing combination chemotherapy (cisplatin carboplatin plus gemcitabine).weakif actionable fgfr alterations: offer erdafitinib.weakconsider antibody drug conjugate sacituzumab govitecan.weakconsider single agent chemotherapy (docetaxel, paclitaxel, vinflunine).weakafter prior platinum-based chemotherapy +/- cpioffer antibody drug conjugate enfortumab vedotin.strongif actionable fgfr alterations: offer erdafitinib.strongif prior cpi: offer pembrolizumab.strongconsider antibody drug conjugate sacituzumab govitecan.weakconsider single agent chemotherapy (docetaxel, paclitaxel, vinflunine).weakfurther treatment ev, cpi, platinum-based therapygeneral statement: offer treatment clinical trials. consider best supportive care (bsc) alone patient candidate cancer-specific systemic therapy.strongif actionable fgfr alterations: offer erdafitinib.weak bsc = best supportive care; cpi = checkpoint inhibitor; ev = enfortumab vedotin; gc = gemcitabine plus cisplatin; fgfr = fibroblast growth factor receptor figure 7.2: flow chart management metastatic urothelial cancer**ev = enfortumab vedotin; fgfr = fibroblast growth factor receptor; gfr = glomerular filtration rate; ps = performance status; cpi=checkpoint inhibitor; pd-l1= programmed deathligand 1; pd= programmed death